News Information_Jiangsu High-wit Medical Ltd.

Welcome to visitJiangsu High-wit Medical Ltd.Enterprise official website

Home page

China Pharmaceutical University visited Jiangsu Haizhi Biotechnology to supervise research and development production and deepen school-enterprise cooperation.

On August 26, 2020, Professor Liu Jianping and Professor Sun Jianguo from China Pharmaceutical University, along with Director Zhu Xuanxuan from Jiangsu Provincial Hospital of Traditional Chinese Medicine, visited Jiangsu Haizhi Biopharmaceutical Co., Ltd. to supervise research and development production work. Both parties had in-depth discussions on the current cooperation project "Research and Development of a Series of Functional Wet Dressings." To continuously deepen the cooperation between the university and the enterprise and to serve the Healthy China strategy, Haizhi Biopharmaceutical has established a deep collaboration with China Pharmaceutical University since November 2017. They jointly develop product formulas, optimize production processes, tackle technical challenges, and closely connect cutting-edge scientific research achievements with market demands, achieving a win-win situation of resource sharing and complementary advantages.

2020

Thorough Investigation! The National Medical Products Administration's "Clearing the Network Action" Addresses These Behaviors

Recently, the National Medical Products Administration issued the 2020 Medical Device "Clearing the Network Action" work plan, requiring adherence to the principles of linking "online" and "offline", and combining information with products. It emphasizes strengthening the management responsibilities of third-party platforms for medical device online trading services and the main responsibilities of medical device online sales enterprises. It also calls for the implementation of local regulatory responsibilities by drug regulatory authorities, increasing monitoring of medical device online transactions, and severely cracking down on illegal and irregular activities.

2020

China's fourth COVID-19 vaccine has been approved to start clinical trials, developed by the Beijing Institute of Biological Products.

2020

< 1 2 3 4 5 >

Jiangsu Haizhi Biopharmaceutical Co., Ltd.

Tel: 025-68535200

Agent to join contact: Xu total 13357821869

OEM/ODM processing contact: Xu total 13357821869

E-mail: service@jshaizhi.cn

Address: Building B2, No.9 Kechuang Avenue, Jiangbei New District, Nanjing

High-wit Micro Mall

High-wit official website

COOKIES

Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy

COOKIES

required

These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.

analyze

These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.

Feature

These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.

advertise

These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.

SEO

Business License